With the lack of public trust and confidence the biggest barrier to SARS-CoV-2 vaccines in the U.S., the risk of granting an emergency use authorization (EUA) to a vaccine with safety issues or questionable efficacy could destroy confidence in future FDA-approved products.

That message was drummed home throughout the Oct. 22 meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee, even though the meeting was convened to shine light on the FDA’s commitment to the scientific process and the many checks being built into the review process and monitoring programs for the vaccines.

Read more